Zobrazeno 1 - 10
of 227
pro vyhledávání: '"C, Bellera"'
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background Classical phase 1 dose-finding designs based on a single toxicity endpoint to assess the maximum tolerated dose were initially developed in the context of cytotoxic drugs. With the emergence of molecular targeted agents and immuno
Externí odkaz:
https://doaj.org/article/3a071f68e9164ced9e5f4a1103f5f284
Autor:
D. Dinart, J. Fraisse, D. Tosi, A. Mauguen, C. Touraine, S. Gourgou, M. C. Le Deley, C. Bellera, C. Mollevi
Publikováno v:
BMC Medical Informatics and Decision Making, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background The main objective of phase I cancer clinical trials is to identify the maximum tolerated dose, usually defined as the highest dose associated with an acceptable level of severe toxicity during the first cycle of treatment. Severa
Externí odkaz:
https://doaj.org/article/7a047fe166cf4466945a8c5fa9d106bd
Autor:
A, Bayle, F, Peyraud, L, Belcaid, M, Brunet, M, Aldea, R, Clodion, P, Dubos, D, Vasseur, C, Nicotra, A, Geraud, M, Sakkal, L, Cerbone, F, Blanc-Durand, F, Mosele, P, Martin Romano, M, Ngo Camus, I, Soubeyran, E, Khalifa, M, Alame, L, Blouin, D, Dinart, C, Bellera, A, Hollebecque, S, Ponce, Y, Loriot, B, Besse, L, Lacroix, E, Rouleau, F, Barlesi, F, Andre, A, Italiano
Publikováno v:
Annals of Oncology. 33:1328-1331
Autor:
J. Palussière, F. Chomy, M. Savina, F. Deschamps, J. Y. Gaubert, A. Renault, O. Bonnefoy, F. Laurent, C. Meunier, C. Bellera, S. Mathoulin-Pelissier, T. de Baere
Publikováno v:
Journal of Cardiothoracic Surgery, Vol 13, Iss 1, Pp 1-9 (2018)
Abstract Background A prospective multicenter phase II trial to evaluate the survival outcomes of percutaneous radiofrequency ablation (RFA) for patients with stage IA non-small cell lung cancer (NSCLC), ineligible for surgery. Methods Patients with
Externí odkaz:
https://doaj.org/article/c909c86094e5412181181a49584f1fa9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
F. Bouteiller, C. Courtinard, S. Gourgou, A. Galvin, F. Dalenc, A. Mailliez, M. Bringuier, S. Delaloge, C. Bellera
Publikováno v:
Revue d'Épidémiologie et de Santé Publique. 71:101788
Autor:
S. Albert, A. Italiano, M. Toulmonde, S. Cousin, R. Bahleda, M. Brahmi, S. Watson, C. Auzanneau, N. Douiri, L. Poignie, B. Lortal, F. Le Loarer, C. Bellera
Publikováno v:
Annals of Oncology. 33:S1242-S1243
Autor:
S Négrier, A Brouquet, F Colrat, P Diez-Andreu, M Chartier, A Prudent, AF Gaudin, S Bénard, S Branchoux, M Roupret, C Bellera
Publikováno v:
Value in Health. 25:S86
Autor:
A. Italiano, A. Bessede, M. Pulido, E. Bompas, S. Piperno-Neumann, C. Chevreau, N. Penel, F. Bertucci, M. Toulmonde, C. Bellera, J. P. Guegan, C. Rey, C. Sautès-Fridman, A. Bougoüin, C. Cantarel, M. Kind, M. Spalato, B. Dadone-Montaudie, F. Le Loarer, J. Y. Blay, W. H. Fridman
Publikováno v:
Nature medicine. 28(6)
Immune checkpoint inhibitors (ICIs) show limited clinical activity in patients with advanced soft-tissue sarcomas (STSs). Retrospective analysis suggests that intratumoral tertiary lymphoid structures (TLSs) are associated with improved outcome in th
Autor:
P. Sargos, E. Stoeckle, A. Giraud, M. Mahe, A. Italiano, M. Kind, M. Toulmonde, A. Mervoyer, A. Ducassou, G. Ferron, C. Bellera, P. Gillon, G. Kantor
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 114:e609